TARGET BP I Clinical Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 300 participants.
Also called NCT02910414
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT02910414
-
- Other papers using this trial's data
- Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT02910414. Randomized; triple masking; primary purpose treatment. Start 2019-07-22 (actual); primary completion 2023-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TARGET BP I Clinical Trial
- Acronym
- TARGET BP I
- Condition
- Hypertension
- Intervention (Drug)
- Dehydrated alcohol
- Intervention (Device)
- Peregrine System Kit (Sham Procedure)
- Lead sponsor
- Ablative Solutions, Inc.
Record details
- Record id
cardio:ct-nct02910414- Content hash
0f0a40a0306aed537a42e9ef8d3b7cac687debe98981bdb822289180a8f937f7